Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06762457 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Single and Multiple Ascending Dose Study of MT-501
A Phase 1 study, sponsored by Mirador Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT06762457 is a Phase 1 study that has completed, run by Mirador Therapeutics. The registered enrollment target is 72 participants.
The verdict
NCT06762457, a Phase 1 study, has completed, sponsored by Mirador Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) with Single and Multiple Ascending Oral Doses of MT-501 in Healthy Adults.
Interventions
- DRUG MT-501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-12-11 |
| Est. Completion | 2025-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06762457
The ClinicalTrials.gov registry entry for NCT06762457 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirador Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MT-501 is the first listed.
NCT06762457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06762457 about?
NCT06762457 is a clinical study titled "A First-in-Human Single and Multiple Ascending Dose Study of MT-501". First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) with Single and Multiple Ascending Oral Doses of MT-501 in Healthy Adults.
What is the current status of trial NCT06762457?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2024-12-11. Estimated completion is 2025-05-22.
What interventions are being tested in trial NCT06762457?
The interventions under investigation include: MT-501 (DRUG).
Who is sponsoring clinical trial NCT06762457?
This trial is sponsored by Mirador Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.